Vaccines

Yvonne Perrie*, Randip Kaur, Malou Henriksen-Lacey

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapter (peer-reviewed)

Abstract

Vaccines continue to offer the key line of protection against a range of infectious diseases; however, the range of vaccines currently available is limited. One key consideration in the development of a vaccine is risk-versus-benefit, and in an environment of perceived low risk, the benefit of vaccination may not be recognised. To address this, there has been a move towards the use of subunit-based vaccines, which offer low side-effect profiles but are generally weakly immunogenic. This can be compensated for by the development of effective adjuvants. Nanotechnology offers key attributes in this field through the ability of nanoparticulates to incorporate and protect antigens from rapid degradation, combined with their potential to effectively deliver the antigens to appropriate cells within the immune system. These characteristics can be exploited in the development of new adjuvants. This chapter will outline the applications of nanosystems in vaccine formulations and consider the mechanisms of action behind a range of formulations.

Original languageEnglish
Title of host publicationFundamentals of pharmaceutical nanoscience
EditorsIjeoma F. Uchegbu, Andreas G. Schätzlein, Woei Ping Cheng, Aikaterini Lalatsa
Place of PublicationNew York (US)
PublisherSpringer
Pages465-491
Number of pages27
ISBN (Electronic)978-1-4614-9164-4
ISBN (Print)978-1-4614-9163-7
DOIs
Publication statusPublished - 1 Nov 2013

Fingerprint Dive into the research topics of 'Vaccines'. Together they form a unique fingerprint.

  • Cite this

    Perrie, Y., Kaur, R., & Henriksen-Lacey, M. (2013). Vaccines. In I. F. Uchegbu, A. G. Schätzlein, W. P. Cheng, & A. Lalatsa (Eds.), Fundamentals of pharmaceutical nanoscience (pp. 465-491). Springer. https://doi.org/10.1007/978-1-4614-9164-4_17